Sort
48,018 grants matching “immunotherapy”
Enhancing Cancer Immunotherapy: Targeting the Tumor and Targeting the Host
$820,359Ronald Levy · Stanford University · R35 · FY2022 · CA
UCSF Autoimmunity Center of Excellence
$820,227University Of California San Francisco · U19 · FY2004 · AI
Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer
$820,052Robert H Vonderheide · University Of Pennsylvania · R01 · FY2020 · CA
Cancer Center Support Grant
$820,000Steven D Leach · Dartmouth College · P30 · FY2020 · CA
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir
$819,850Marina Caskey · Rockefeller University · U01 · FY2017 · AI
Immunoprevention and immunosurveillance of human non-viral cancers
$819,666Olivera J Finn · University Of Pittsburgh At Pittsburgh · R35 · FY2018 · CA
ASTHMA AND ALLERGIC DISEASES CENTER
$819,544University Of Virginia Charlottesville · U19 · FY2000 · AI
Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS Factor
$819,364Victor Lobanenkov · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology
$819,000Hongbo Chi · St. Jude Children'S Research Hospital · U01 · FY2023 · CA
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology
$819,000Hongbo Chi · St. Jude Children'S Research Hospital · U01 · FY2025 · CA
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer
$818,940Grant H Risdon · Cancure, Llc · R44 · FY2019 · CA
MOUNT SINAI COMMUNITY CLINICAL ONCOLOGY PROGRAM
$818,903Mount Sinai Medical Center (Miami Beach) · U10 · FY2004 · CA
Fibroblast Heterogeneity in Pancreatic Cancer
$818,876David Tuveson · Cold Spring Harbor Laboratory · R01 · FY2021 · CA
The role of BCL11B in T lineage fate during human thymopoiesis and pluripotent stem cell differentiation
$818,795Gay Miriam Crooks · University Of California Los Angeles · R01 · FY2024 · AI
Using trained immunity-inhibiting nanobiologics to achieve tolerance of heart allografts in non-human primates
$818,648Joren C Madsen · Icahn School Of Medicine At Mount Sinai · P01 · FY2024 · AI
The role of BCL11B in T lineage fate during human thymopoiesis and pluripotent stem cell differentiation
$818,621Gay Miriam Crooks · University Of California Los Angeles · R01 · FY2025 · AI
Allergen T cell epitopes and phenotypes in peanut allergy and immunotherapy
$818,508William W. Kwok · Benaroya Research Inst At Virginia Mason · U19 · FY2021 · AI
PEDIATRIC AIDS CLINICAL TRIAL UNIT
$818,332Univ Of Massachusetts Med Sch Worcester · U01 · FY2001 · AI
Thriving Beyond Treatment: A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
$817,829Giselle Katiria Perez-Lougee · Massachusetts General Hospital · R37 · FY2025 · CA
NEXT-GENERATION HUMAN PROSTATE CANCER COCULTURES TO OPTIMIZE AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T-CELL IMMUNOTHERAPY
$817,785Fred Hutchinson Cancer Research Center · · FY2019 · Defense Health Agency
Johns Hopkins Rheumatic Diseases Resource-based Core Center (Johns Hopkins RDRCC)
$817,728Antony Rosen · Johns Hopkins University · P30 · FY2021 · AR
Clinical Protocol and Data Management
$817,523Jeffrey A Meyerhardt · Dana-Farber Cancer Inst · P30 · FY2025 · CA
TARGETING PRMT3-IGF2BP1 AXIS-MEDIATED EPITRANSCRIPTOMIC REPROGRAMMING AS A NOVEL THERAPEUTIC STRATEGY TO OVERCOME IMMUNOTHERAPY RESISTANCE IN CCRCC
$817,496The Univeristy Of Texas M.D. Anderson Cancer Center · · FY2025 · Defense Health Agency
Cancer Imaging and Therapy Analysis Platform (CITAP)
$817,362Madhusudhana Gargesha · Bioinvision, Inc. · R44 · FY2018 · CA
Bispecific Antibody Therapeutics for Neuroblastoma and Diffuse Midline Glioma
$817,202James M Olson · Seattle Children'S Hospital · U01 · FY2024 · CA